Benzinga | May 23, 2021 06:41PM EDT

NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH on Monday May 24

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis. Conference call and webcast details are as follows:

Live Conference CallDomestic Callers: (844) 873-0551International Callers: (602) 563-8472Passcode: 9393531

Live and Archived Webcast For the live or archived webcast, please visit the "Investors & Media" section of NGM's website at https://ir.ngmbio.com/. The webcast will be archived for 30 days.

Archived Conference Call Domestic Callers: (855) 859-2056International Callers: (404) 537-3406Passcode: 9393531